Preparing for Your First FDA Inspection: A Step-by-Step Guide

Understanding FDA's Inspection Approach

Begin by establishing whether the operation is relying on 503A or registered under 503B, and which activities and records are in scope. FDA may inspect compounding facilities for different reasons; a state-board inspection is not interchangeable with an FDA cGMP inspection. FDA’s compounding questions and answers explains the oversight distinction.

Regardless of the trigger, inspectors use a systems-based approach that evaluates your operation holistically rather than checking individual items in isolation.

The 6-System Inspection Framework

The six-system structure is a useful organizing framework for drug cGMP preparation, especially for a 503B operation. It is not a promise that every 503A inspection will follow the same sequence or scope.

1. Quality System

This is the umbrella system that governs all others. Inspectors evaluate your overall quality management structure: CAPA processes, deviation handling, change control, management review, internal audits, and complaint handling. A weak quality system suggests that problems in other systems are not being detected or corrected.

2. Facilities and Equipment System

Covers your physical infrastructure: cleanroom design and classification, HVAC systems, differential pressure monitoring, equipment qualification and maintenance, calibration programs, and cleaning validation. Inspectors will walk your facility, check gauges, review maintenance logs, and verify that your environmental controls match your documentation.

3. Materials System

Evaluates how you manage incoming materials: supplier qualification, receiving procedures, identity testing, Certificate of Analysis review, storage conditions, inventory control, and material rejection/disposition processes. Inspectors may trace a specific ingredient from receipt through use in a batch record.

4. Production System

Examines your compounding operations: batch records, formula management, in-process controls, process validation (for 503B), equipment cleaning between products, and yield reconciliation. Inspectors will select batch records and trace every step from formula to finished product.

5. Packaging and Labeling System

Reviews how finished preparations are packaged, labeled, and stored before dispensing. This includes label accuracy, beyond-use dating, storage conditions, and controls to prevent mix-ups.

6. Laboratory Control System

Covers all testing activities: environmental monitoring, sterility testing, endotoxin testing, potency testing (for 503B), stability programs, and laboratory equipment calibration. Inspectors will review raw data, not just final results.

Pre-Inspection Checklist

While you should always be inspection-ready, there are specific preparations to make when you know an inspection is imminent or likely.

• Document organization: Ensure all SOPs are current (no expired versions in use), all training records are complete and accessible, and all equipment calibration and maintenance records are up to date. An inspector should be able to request any document and have it produced within minutes, not hours.
• Self-inspection: Conduct a thorough mock inspection using a standardized checklist that covers all six FDA systems. Document findings and address any gaps before the real inspection. Assign an owner and evidence location to each applicable item rather than targeting an arbitrary checklist length.
• CAPA review: Ensure all open CAPAs are progressing on schedule. Close any CAPAs that have completed effectiveness verification. Overdue CAPAs are a red flag that inspectors specifically look for.
• Environmental data review: Review recent environmental monitoring data for any trends, excursions, or gaps. Ensure investigations have documented status, impact assessment and follow-up. Keep unresolved issues visible; do not close them merely to prepare for an inspection.
• Training status: Verify that all personnel have current competency assessments and that no assessments are overdue. Ensure new employees hired in the past 6 months have completed all required initial training.
• Batch record review: Randomly sample recent batch records and verify completeness — every field filled, every signature present, every deviation noted and investigated.

Day-of Preparation

When inspectors arrive, your response sets the tone for the entire inspection.

• Designated escort: Assign a knowledgeable person (typically the quality manager or pharmacy director) to accompany inspectors at all times. This person should be able to answer questions or quickly locate someone who can.
• Document staging area: Set up a dedicated space where inspectors can review documents. Have your organizational chart, facility map, SOP index, and key compliance summaries readily available.
• Staff preparation: Brief all staff on inspection protocols — answer questions honestly, do not volunteer information beyond what is asked, and immediately notify the escort if an inspector requests something unusual.
• Parallel documentation: Have someone take detailed notes on every inspector request, every document provided, and every observation made. This record is invaluable for responding to any findings.

Common 483 Observations

Certain inspection findings appear repeatedly across compounding pharmacy inspections. Knowing these patterns helps you prioritize your preparation:

• Inadequate environmental monitoring: A sampling plan that does not match operations, missing investigation evidence, or undocumented trend review.
• Incomplete batch records: Missing signatures, undocumented deviations, calculation errors without correction documentation.
• Training deficiencies: Overdue competency assessments, missing media fill documentation, no evidence of remediation after failed assessments.
• SOP non-compliance: Expired SOPs still in use, staff unable to locate current versions, procedures that do not match actual practice.
• Calibration lapses: Overdue calibrations, missing NIST traceability, no out-of-calibration impact assessments.
• Data integrity issues: Incomplete audit trails, shared login credentials, backdated records.

After the inspection: separate observations from conclusions

A Form FDA 483 documents inspectional observations; it is not FDA’s final determination of whether a facility violates the law. See FDA’s Form 483 FAQs.

FDA generally allows 15 business days for a voluntary written response, as described in its inspection guidance overview. Check the correspondence actually received. For each observation, distinguish completed corrections from planned actions, identify an owner and realistic date, attach evidence, and explain how effectiveness will be checked. Do not fabricate closure evidence to meet a response date.

Maintain the request log, copies supplied, final observations and response evidence together. Connect systemic findings to your CAPA process, affected personnel records and approved procedures.

Building an Always-Ready Culture

Make record review part of normal work: review scheduled monitoring, resolve missed activities, check personnel eligibility, and assess overdue corrective actions. Preserve superseded SOP versions for historical review while clearly identifying the current approved procedure. Automation can help route work, but assigned staff must evaluate results and follow through.

Use the USP <797> self-assessment to find documentation gaps and the enforcement analysis to review published observations with their sampling limits. For CompliRx, request a demonstration that retrieves a selected record and its supporting evidence. A dashboard score does not predict an inspection outcome.